Oral contraceptives and benign tumors of the liver

L. H. Smith, J. G. Fitz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In recent years the prevalence of benign tumors of the liver has increased to the point that they must now be considered in the differential diagnosis of a variety of symptoms in women at risk. It is important to distinguish hepatic adenoma from focal nodular hyperplasia for the former may be complicated by severe hemorrhage and is clearly linked to prolonged use of oral contraception. Focal nodular hyperplasia has an excellent prognosis and, despite some reports to the contrary, there is no clear evidence that synthetic hormone use has resulted in a change in the frequency of this tumor. It is estimated that the annual incidence of hepatic adenoma is now 3.4 cases per 100,000 oral contraceptive users and at this rate about 320 new cases are expected each year. There is no question that careful scrutiny of the group at risk offers the best chance of preventing serious morbidity from hepatic adenoma.

Original languageEnglish (US)
Pages (from-to)260-267
Number of pages8
JournalWestern Journal of Medicine
Volume140
Issue number2
StatePublished - 1984

Fingerprint

Oral Contraceptives
Adenoma
Focal Nodular Hyperplasia
Liver
Neoplasms
Contraception
Differential Diagnosis
Hormones
Hemorrhage
Morbidity
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Oral contraceptives and benign tumors of the liver. / Smith, L. H.; Fitz, J. G.

In: Western Journal of Medicine, Vol. 140, No. 2, 1984, p. 260-267.

Research output: Contribution to journalArticle

@article{31becfac5f4b4cee846664adafdb19d2,
title = "Oral contraceptives and benign tumors of the liver",
abstract = "In recent years the prevalence of benign tumors of the liver has increased to the point that they must now be considered in the differential diagnosis of a variety of symptoms in women at risk. It is important to distinguish hepatic adenoma from focal nodular hyperplasia for the former may be complicated by severe hemorrhage and is clearly linked to prolonged use of oral contraception. Focal nodular hyperplasia has an excellent prognosis and, despite some reports to the contrary, there is no clear evidence that synthetic hormone use has resulted in a change in the frequency of this tumor. It is estimated that the annual incidence of hepatic adenoma is now 3.4 cases per 100,000 oral contraceptive users and at this rate about 320 new cases are expected each year. There is no question that careful scrutiny of the group at risk offers the best chance of preventing serious morbidity from hepatic adenoma.",
author = "Smith, {L. H.} and Fitz, {J. G.}",
year = "1984",
language = "English (US)",
volume = "140",
pages = "260--267",
journal = "Western Journal of Medicine",
issn = "0093-0415",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Oral contraceptives and benign tumors of the liver

AU - Smith, L. H.

AU - Fitz, J. G.

PY - 1984

Y1 - 1984

N2 - In recent years the prevalence of benign tumors of the liver has increased to the point that they must now be considered in the differential diagnosis of a variety of symptoms in women at risk. It is important to distinguish hepatic adenoma from focal nodular hyperplasia for the former may be complicated by severe hemorrhage and is clearly linked to prolonged use of oral contraception. Focal nodular hyperplasia has an excellent prognosis and, despite some reports to the contrary, there is no clear evidence that synthetic hormone use has resulted in a change in the frequency of this tumor. It is estimated that the annual incidence of hepatic adenoma is now 3.4 cases per 100,000 oral contraceptive users and at this rate about 320 new cases are expected each year. There is no question that careful scrutiny of the group at risk offers the best chance of preventing serious morbidity from hepatic adenoma.

AB - In recent years the prevalence of benign tumors of the liver has increased to the point that they must now be considered in the differential diagnosis of a variety of symptoms in women at risk. It is important to distinguish hepatic adenoma from focal nodular hyperplasia for the former may be complicated by severe hemorrhage and is clearly linked to prolonged use of oral contraception. Focal nodular hyperplasia has an excellent prognosis and, despite some reports to the contrary, there is no clear evidence that synthetic hormone use has resulted in a change in the frequency of this tumor. It is estimated that the annual incidence of hepatic adenoma is now 3.4 cases per 100,000 oral contraceptive users and at this rate about 320 new cases are expected each year. There is no question that careful scrutiny of the group at risk offers the best chance of preventing serious morbidity from hepatic adenoma.

UR - http://www.scopus.com/inward/record.url?scp=0021753033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021753033&partnerID=8YFLogxK

M3 - Article

C2 - 6730471

AN - SCOPUS:0021753033

VL - 140

SP - 260

EP - 267

JO - Western Journal of Medicine

JF - Western Journal of Medicine

SN - 0093-0415

IS - 2

ER -